PsiThera

PsiThera is a private, pre-clinical stage biotech aiming to disrupt the immunology market by creating oral 'antibody-in-a-pill' alternatives to injectable biologics. Its core differentiator is the QUAISAR platform, a physics-native, AI-accelerated computational engine designed to model biologically relevant protein motion and reveal transient, druggable pockets on challenging targets. The company is advancing a pipeline of early-stage programs against targets like sTNFα, mOX40L, and TL1A for conditions such as rheumatology, inflammatory bowel disease, and atopic dermatitis.

QUAISAR (Quantum, AI and Structure-Activity Relationships) platform: A physics-native, AI-accelerated computational platform that models biologically relevant protein motion to reveal transient druggable pockets. It integrates structural biophysics (HDX-MS, NMR, Cryo-EM), predictive simulations, and human expertise via the PsiVision data environment to design oral small molecules for difficult targets.

PsiThera competes directly with developers of biologic therapies (monoclonal antibodies) in immunology, which are the standard of care. It also competes with other biotechs pursuing oral small molecules for cytokine targets, though its platform approach focused on protein dynamics is a key differentiator. Large pharma companies with extensive immunology portfolios are both competitors and potential partners.